| Name | Title | Contact Details |
|---|
St. Luke`s, a regional health care system, offers a comprehensive continuum of care serving the 17-county region of northeastern Minnesota, northwestern Wisconsin and the Upper Peninsula of Michigan. The system includes St. Luke`s Hospital in Duluth, Minnesota, Lake View Hospital in Two Harbors, Minnesota, and 11 primary and 27 specialty clinics. Primary care clinics are located in Duluth, Hermantown, Hibbing, Two Harbors, Mountain Iron and Silver Bay, Minnesota, and Ashland and Superior, Wisconsin. Urgent care and Q Care express medical services are also available. St. Luke`s is designated by the American College of Surgeons and the state of Minnesota Department of Health as a Level II trauma center. St. Luke`s Regional Cancer Center offers treatments including Stereotactic Radiosurgery (SRS) and radiation oncology. St. Luke`s Regional Heart Center includes cardiology, cardiothoracic surgery, cardiac rehab services and catheterization lab. Other specialties include obstetrics, gynecology, plastic surgery, pulmonary medicine, allergy, neurosurgery, dermatology, endocrinology, gastroenterology, infectious disease, surgery, occupational health, orthopedics and sports medicine, pediatrics, physical medicine and rehab, rheumatology, psychiatry, urology, hospice and home care. With the University of Minnesota Duluth Medical School, St. Luke`s conducts clinical research in the areas of cancer, lung and heart disease through the Whiteside Institute for Clinical Research.
Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care. Aerie Pharmaceuticals discovers, develops, and commercializes first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye. See the future of eye care with Aerie.
Marcon Group Inc is a San Rafael, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.
Medical Innovations International is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.